<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05628961</url>
  </required_header>
  <id_info>
    <org_study_id>SRI-HOPO-01</org_study_id>
    <nct_id>NCT05628961</nct_id>
  </id_info>
  <brief_title>Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics</brief_title>
  <official_title>An Open-Label, First-In-Human Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics, and Excretion in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SRI International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SRI International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to define the safety and tolerability profile of oral, single&#xD;
      ascending dose (SAD) levels of HOPO 14-1 capsules in cohorts of healthy participants and to&#xD;
      assess the pharmacokinetic (PK) and excretion profile of HOPO 14-1. The study hypothesis is&#xD;
      that a single dose of HOPO 14-1 will be safe and tolerable up to 7500 mg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The currently available therapy for radionuclide internal contamination is suboptimal.&#xD;
      Pharmacological and toxicological data support the clinical development of HOPO 14-1 for&#xD;
      decorporation of radionuclides.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2022</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Drug-Related Adverse Events</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Adverse Events by Maximum Severity</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Events</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Time to Reach Cmax (Tmax)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve up to the Last Blood Collection Time with a Measurable Concentration (AUClast)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-Life (t 1/2)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution after Oral Administration (V/F)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Systemic Clearance Rate (CL/F)</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount Excreted in Urine</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount Excreted in Feces</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Toxicity;Chemical</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: 2500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: 5000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7: 7500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HOPO 14-1</intervention_name>
    <description>HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.</description>
    <arm_group_label>Cohort 1: 100 mg</arm_group_label>
    <arm_group_label>Cohort 2: 200 mg</arm_group_label>
    <arm_group_label>Cohort 3: 500 mg</arm_group_label>
    <arm_group_label>Cohort 4: 1200 mg</arm_group_label>
    <arm_group_label>Cohort 5: 2500 mg</arm_group_label>
    <arm_group_label>Cohort 6: 5000 mg</arm_group_label>
    <arm_group_label>Cohort 7: 7500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability of participant to understand the requirements of the study, provide written&#xD;
             informed consent, and agree to abide by the study requirements&#xD;
&#xD;
          -  Agree to use contraception from time of screening until 14 days after dosing (Day 14)&#xD;
             if female is of childbearing potential or male is with female partner of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  In good general health based on medical history, physical examination (PE), and&#xD;
             screening evaluations.&#xD;
&#xD;
          -  Negative urine or blood screen for drugs of abuse (except if participant provides&#xD;
             prescription justifying use prior to urine screen).&#xD;
&#xD;
          -  Body weight ≥ 50 kilogram (kg) and ≤ 110 kg. If body weight is over 110 kg, then body&#xD;
             mass index (BMI) will be considered and must be ≤ 40 kg/m^2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness of a participant to give written informed consent or comply&#xD;
             with study protocol.&#xD;
&#xD;
          -  Any hematology, chemistry, coagulation, or urinalysis value on screening labs defined&#xD;
             in the United States Food and Drug Administration (FDA) Guidance for Industry Toxicity&#xD;
             Grading Scale as Grade 1 or higher.&#xD;
&#xD;
          -  Any clinically significant electrocardiogram (ECG) abnormality&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Active substance abuse or history of any medical or psychiatric condition that would&#xD;
             jeopardize the participant's safety or the participant's ability to comply with the&#xD;
             protocol.&#xD;
&#xD;
          -  Received an organ transplant (solid or bone marrow).&#xD;
&#xD;
          -  Received a blood transfusion within 3 months of dosing.&#xD;
&#xD;
          -  Difficulty swallowing tablets or capsules.&#xD;
&#xD;
          -  Febrile illness or significant infection within 7 days of dosing.&#xD;
&#xD;
          -  Symptoms of hypotension (lightheadedness, syncope, balance disturbances, or extreme&#xD;
             fatigue) within 48 hours of dosing.&#xD;
&#xD;
          -  Hepatitis B virus surface antigen (HBsAg) positive or serologic (antibody positive)&#xD;
             evidence of infection with hepatitis C virus (HCV) or human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
          -  Tested positive for SARS-CoV-2 (COVID-19) within 21 days of dosing.&#xD;
&#xD;
          -  Chelation therapy (e.g., ethylenediaminetetraacetic acid [EDTA], diethylenetriamine&#xD;
             pentaacetate [DTPA]) in the past year.&#xD;
&#xD;
          -  Use of laxatives, antibiotics, and/or antacids within 7 days of dosing.&#xD;
&#xD;
          -  Use of investigational drugs within 60 days of dosing or 5 half-lives, whichever is&#xD;
             longer.&#xD;
&#xD;
          -  Received a vaccination within 30 days of dosing.&#xD;
&#xD;
          -  Potential allergic reaction to product (oleic acid or HOPO 14-1 product).&#xD;
&#xD;
          -  Past or current medical problems or findings from physical examination (PE) or&#xD;
             laboratory testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>SRI International</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>734-527-4200</phone>
    <email>clinical-trials@sri.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Director Clinical Operations</last_name>
    <phone>734-527-4200</phone>
    <email>clinical-trials@sri.com</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Internal Radionuclide Contamination</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

